Search
Ivacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigational[L6841] Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF. … [A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsSynonyms: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamidePemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalThis malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality. … growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesrsPSMA Vaccine
go.drugbank.com/drugs/DB06361ApprovedWithdrawnrsPSMA Vaccine is a subunit vaccine based on a novel rsPSMA protein that represents the entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003). … Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases.
Milsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigational[A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes. … [L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMethadyl acetate
go.drugbank.com/drugs/DB01433ExperimentalIllicitA narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.
Palovarotene
go.drugbank.com/drugs/DB05467ApprovedIt first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP. … ], which are derivatives of [vitamin A].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersDinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalneuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. … It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk
Flunisolide
go.drugbank.com/drugs/DB00180ApprovedFlunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. … It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersProducts: Aerobid-M, FLUNISOLIDE EGRose bengal
go.drugbank.com/drugs/DB11182ApprovedInvestigationalThe clinical applications of rose bengal as injectable formulation under the name PV-10 in melanoma, breast cancer and skin conditions such as eczema and psoriasis are being investigated in clinical trials … Rose bengal is a pink stain derived as an analogue of fluorescein. Its disodium salt in ophthalmic solutions has been used as a diagnostic agent in suspected damage to conjunctival and corneal cells.
Categories: Compounds used in a research, industrial, or household settingIdelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalFor the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other … The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index